Five recent drug target discoveries for pancreatic cancer
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
List view / Grid view
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
The ICR has revealed that during drug discovery, researchers should not use general search engines and vendor catalogue information to decide on their use of chemical probes.
A compound that has antimicrobial properties has been found by researchers, which could be used to combat drug-resistant infections.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
A world-first compound that can keep cells alive and functioning in a healthy state could be revolutionary for medical emergencies.
The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
Chronic inflammatory processes in ageing brains lead to lymphoma cells that have entered the brain tissue being retained.
A new platform has enabled an unprecedented level of control over individual molecules and particles on a chip for high-throughput analysis.
A new study has found a small molecule which prevents cancer cells from mutating and becoming resistant to chemotherapy.
Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving…
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
An immunoassay developed to analyse small molecules has shown 50 times greater accuracy than current systems of analytical techniques...
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.